Early Asset Acquisition
35% Trial Budget Reduction
Significance Efficacy in a Rare Disease Trial Faster
Objective Go / No Go Decisions
Optimizing Patient Stratification
Value of Your Data
Licencing Deal after Phase IIa Results Announced
Confirming MoA through Advanced Imaging Endpoints
Collaboration to Deploy Artificial Intelligence Imaging Methodologies for Reliable Early Efficacy Readouts
Collaboration to Accelerate Development of Novel Breakthrough Therapies for Patients with Inflammatory Bowel Disease
Collaboration in development of a combination therapy in Metastatic Melanoma
Partnership to Advance Clinical Development of DPX-Survivac in the Treatment of Solid Tumors
Partnership to Validate Predictive Imaging Markers for Treatment Response in Solid Tumors.
Partnership to Augment Clinical Decision Making with AI Driven Methodology for Ulcerative Colitis Histopathological Image Analysis
Partnership to Develop Multi-Omics-Based Machine Learning Models to Study Glioblastoma Multiforme
Partnership to Maximize Chances of Success for Immuno-Oncology Companies through the use of Advanced Imaging Strategies.
Partnership to Objectively Assess Patient Response to a Novel Cell-Based Therapy in a Rare Paediatric Orthopaedic Condition.
Partnership to Advance Connectivity and Interoperability in Clinical Trials of Rheumatic Diseases
Partnership with CNS Pharmaceuticals Partner to Further the Development of Berubicin